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        T cell acute lymphoblastic leukemia (T-ALL) is 
a disease induced by malignant transformation 
of T lymphocytes that affl   icts mainly children 
and adolescents (  1  ). Although treatment out-
come in T-ALL has improved in recent years, 
patients with relapsed disease continue to have 
dismal prognosis, despite the use of protocols 
involving hematopoietic stem cell transplanta-
tion. It is thus very important to identify and 
study the molecular pathways that control both 
induction of transformation and treatment resis-
tance in this particular type of leukemia. Recent 
compelling evidence demonstrated that activat-
ing mutations in the   NOTCH1   gene are the 
trigger for cell transformation in the majority of 
T-ALL patients. 
  Notch1 is a transmembrane receptor that 
controls the diff  erentiation of multiple cell types, 
including cells of the immune system (  2  ). More 
specifi  cally, signaling through the NOTCH1 re-
ceptor orchestrates the development of T lym-
phocytes from uncommitted hematopoietic stem 
cells (  3  –  5  ). Although NOTCH1 signaling is 
required for T cell development (  6, 7  ), aberrant 
activation of the pathway can lead to disease; 
     50% of T-ALL cases harbor activating mutations 
in the   NOTCH1   gene (  8  ). Similar mutations 
were found in several mouse models of T cell leu-
kemia (  9  –  12  ). Very recent evidence showed that 
NOTCH1 pathway activation can induce multi-
ple downstream signaling pathways and genes/
targets, including the NF-kB pathway (  13  –  15  ) 
and the transcription factor c-Myc (  16  –  18  ). 
  The majority of the T-ALL NOTCH1-acti-
vating mutations truncate the C terminus of 
the protein, called the PEST domain because of 
the high frequency of P-E-S-T amino acids. As the 
PEST domain is believed to be essential for pro-
teasome-dependent degradation of NOTCH1, 
these fi  ndings suggest that NOTCH1 protein 
stability could be an important regulator of intra-
cellular signaling thresholds and that abrogation 
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  Recent studies have shown that activating mutations of NOTCH1 are responsible for the 
majority of T cell acute lymphoblastic leukemia (T-ALL) cases. Most of these mutations 
truncate its C-terminal domain, a region that is important for the NOTCH1 proteasome-
mediated degradation. We report that the E3 ligase FBW7 targets NOTCH1 for ubiquitina-
tion and degradation. Our studies map in detail the amino acid degron sequence required 
for NOTCH1  –  FBW7 interaction. Furthermore, we identify inactivating FBW7 mutations in a 
large fraction of human T-ALL lines and primary leukemias. These mutations abrogate the 
binding of FBW7 not only to NOTCH1 but also to the two other characterized targets, 
c-Myc and cyclin E. The majority of the FBW7 mutations were present during relapse, and 
they were associated with NOTCH1 HD mutations. Interestingly, most of the T-ALL lines 
harboring FBW7 mutations were resistant to     -secretase inhibitor treatment and this 
resistance appeared to be related to the stabilization of the c-Myc protein. Our data sug-
gest that FBW7 is a novel tumor suppressor in T cell leukemia, and implicate the loss of 
FBW7 function as a potential mechanism of drug resistance in T-ALL. 1826 FBW7 MUTATIONS IN T CELL LEUKEMIA | Thompson et al.
  We demonstrate that FBW7 targets NOTCH1, and per-
form a detailed mapping of their interaction by identify-
ing a degron in the NOTCH1 PEST domain, which is 
centered on a conserved threonine, T  2512  . Alteration of this 
degron prevents FBW7-mediated ubiquitination of nuclear 
NOTCH1. Furthermore, we show that loss of FBW7 occurs 
frequently in T-ALL, as we identify FBW7 mutations in both 
T-ALL cell lines and primary tumors that carry NOTCH1-
activating mutations. These mutations target specifi  c residues 
in the FBW7-binding pocket and render the molecule in-
capable of binding NOTCH1, c-Myc, and cyclin E. FBW7 
mutations usually pair with NOTCH1-HD mutations, sug-
gesting a functional cooperation between the two events 
in the induction of NOTCH pathway activation. Finally, 
we demonstrate that there is an overrepresentation of FBW7 
mutations in relapse patient samples, and that all T-ALL cell 
lines carrying FBW7 mutations are resistant to      -secretase 
inhibitor treatment, suggesting that FBW7 inactivation could 
serve as a mechanism of treatment resistance, potentially 
caused by the stabilization of the downstream NOTCH1 
  eff  ector c-Myc. 
of the NOTCH1 degradation machinery could predispose 
cells for transformation. The exact mechanisms by which the 
PEST domain confers instability to N1-IC remain unclear. 
Early genetic studies in   Caenorhabditis elegans   identifi  ed a 
candidate silencer of Notch, the E3 ubiquitin ligase SEL-10 
(FBW7/hAGO/hCDC4, which is referred to hereafter as 
FBW7) (  19  ). FBW7 is a potent tumor suppressor (  20  ), targeting 
proteins such as cyclin E, c-Myc, and c-Jun for   proteasomal 
degradation (  21  –  23  ). Several reports have demonstrated that 
FBW7 can also target nuclear Notch1 and Notch4 for ubiqui-
tination and can suppress Notch signaling (  24, 25  ); however, 
the detailed biochemical nature and the in vivo   physiological 
relevance in development and cell transformation of this inter-
action remain unknown. Moreover, Fbw7-defi  cient embryos 
die around day 10.5 because of defects in vascular development. 
Two such lines were simultaneously generated by diff  erent 
groups, and whole embryo lysates contained elevated levels of 
Notch1 protein in one case, but not the other (  26, 27  ), raising 
questions about the importance of Fbw7 for the degradation 
of Notch1 or suggesting tissue-specifi  c interactions between 
the two proteins. 
  Figure 1.     Physical and functional association between FBW7 and NOTCH1. (A) Schematic depiction of the NOTCH1 (N1) protein domains, and 
N1-IC WT (N1-IC  WT  ) and 82 and 162      PEST mutants (N1-IC      82   and  N1-IC     162  ). Asterisk denotes L1601P mutation. The FBW7 degron is highlighted in gray. 
LNR, LIN-Notch repeat domain; RAM, RBJ-       –  associated module; TAD, transcriptional activation domain; PEST, P-E-S-T  –  rich domain; HD, heterodimeriza-
tion domain. (B and C) Coimmunoprecipitation experiments using anti-Flag beads or anti-HA beads, showing interaction between DN FBW7 and N1-IC  WT , 
but DN FBW7 (D) does not interact with N1-IC      82   and  N1-IC     162  . (E) Cotransfection with FBW7      repressed  N1 L1601P   (P          0.02), but not N1  L1601P-    82  , in re-
porter assays using a CSL luciferase reporter. pCDNA3.1 represents the control,   “  empty  ”   expression vector. Error bars represent the SD of duplicate wells. JEM VOL. 204, August 6, 2007 
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We and others have previously shown that this mutation 
found in T-ALL patients (  8  ) can induce NOTCH1 activity 
(  15  ). As evident from   Fig. 1 E  , FBW7      signifi  cantly (P       0.02) 
blocked the activation induced by N1  L1601P  . Similar results 
were obtained using N1-IC (unpublished data). Cotransfec-
tion of DN FBW7 enhanced NOTCH1 activation (  Fig. 1 E  ) 
and could antagonize the eff  ect of the full-length FBW7      
(not depicted). On the other hand, an L1601P mutant that also 
lacked the C-terminal 82 amino acids of the PEST domain 
(N1  L1601P-     82  ) was unaff  ected by FBW7     . These observations 
confi  rm that FBW7 can target and suppress the activity of 
NOTCH1-HD mutants found in T-ALL, and suggest that 
PEST deletion is an effi   cient   “  escape  ”   mechanism that pro-
motes cell transformation. 
  A T  2512  -centered degron controls the interaction 
of NOTCH1 with FBW7 
  Specifi  c F-box protein binding sites, termed degrons, have 
been characterized for several FBW7 substrates. In each 
confi  rmed case, the degron contains a crucial threonine residue 
that must be phosphorylated to allow recognition by FBW7. 
This in mind, we chose to analyze four threonine-  containing 
    RESULTS   
  Physical and functional interaction between FBW7 
and oncogenic NOTCH1 mutants 
    Fig. 1 A   schematically displays the NOTCH1 and N1-IC pro-
teins and maps the potential sites of the FBW7 interactions 
discussed in our article.  To confi  rm that NOTCH1 and FBW7 
physically interact, we performed coimmunoprecipitation 
studies using a dominant-negative (DN) FBW7 that contains 
the substrate-recognizing WD40 repeats of FBW7, but lacks 
the F-box domain that recruits ubiquitination machinery (  Fig. 
3 A  ). As shown in   Fig. 1 (B and C)  , we detected both N1-IC 
and DN FBW7 in the same precipitated immunocomplex. 
Importantly, this interaction required an intact PEST domain, 
as two diff  erent N1-IC mutants lacking the C-terminal 162 or 
82 amino acids (N1-IC       162   and N1-IC       82  , respectively) failed 
to coimmunoprecipitate with DN FBW7 (  Fig. 1 D  ). 
  We then assessed the functionality of this interaction by 
monitoring the ability of FBW7 (      isoform) to reduce the ac-
tivation of a NOTCH1 (RBP-J/CSL)-dependent   luciferase 
reporter. To induce NOTCH1 activation, we generated a full-
length NOTCH1 construct that contains a leucine-to-proline 
substitution in the heterodimerization (HD) domain (N1  L1601P  ). 
  Figure 2.     Mutational analysis of the FBW7 NOTCH1 degron. (A) Coimmunoprecipitation experiment using threonine mutants of N1-IC (N1-IC  T2133A , 
N1-IC  T2467A ,  N1-IC T2484A  , and N1-IC  T2512A  ) and DN FBW7. Only N1-IC  T2512A   was unable to coimmunoprecipitate with DN FBW7. (B) Cell lysates from Bosc23 
cells transfected with N1  L1601P   or  N1 L1601P-T2512A   and  FBW7     were used for luciferase reporter assays. N1  L1601P-T2512A   was not repressed by FBW7     . (C) Cell 
lysates from HeLa cells transfected with full-length N1 mutants were used for luciferase reporter assays. N1  L1601P-    82   and  N1 L1601P-T2512A   induced a 15- and 
5-fold increase in transcriptional activity, respectively, compared with N1  L1601P  . (D) In vivo ubiquitination assay using Bosc23 cells transfected with 
N1-IC  WT ,  N1-IC     82  , or N1-IC  T2512A   with or without SCF  FBW7       (SKP1, CUL1, ROC1, and FBW7     ) and Ub-HA. SCF  FBW7       enhanced polyubiquitination of N1-IC  WT , 
but not of N1-IC      82   or  N1-IC T2512A  . (E) A negative charge is required at position 2516 (T+4). Interaction with DN FBW7 is partially preserved with N1-IC  E2516D , 
but abolished with N1-IC  E2516A  . (F) Mutation of two CDK8 phosphorylation sites prevents N1-IC interaction with FBW7. A mutant lacking both S  2514   and 
S  2517   (N1-IC S2514A-S2517A  ) did not coimmunoprecipitate with DN FBW7. Error bars represent the SD of duplicate wells.     1828 FBW7 MUTATIONS IN T CELL LEUKEMIA | Thompson et al.
that N1  L1601P-T2512A   produced a fi  ve-fold increase in NOTCH1 
activity in HeLa cells compared with N1  L1601P   (  Fig. 2 C  ). 
We should note that the diff  erence in N1  L1601P  -induced tran-
scriptional activation in   Fig. 2 (B and C)   is caused by the 
  utilization of two diff  erent cell lines for the   luciferase re-
porter assays. 
  To confi  rm that N1-IC  T2512A   cannot be ubiquitinated by 
FBW7, we transfected Bosc23 cells with N1-IC  WT  , N1-IC       82  , 
or N1-IC  T2512A   in the presence or absence of the SCF  FBW7       
complex. To preserve ubiquitin conjugates, cells were treated 
with the proteasome inhibitor MG132 6 h before lysis in a 
buff  er containing   N  -ethyl maleimide. HA-ubiquitin immuno-
precipitates were further probed for NOTCH1 expression 
(  Fig. 2 D  ). Cotransfection of SCF  FBW7       increased polyubiqui-
tination of N1-IC  WT  , but not N1-IC       82   or N1-IC  T2512A  . The 
point mutant retained a higher level of polyubiquitination 
compared with N1-IC       82   that was not enhanced by SCF  FBW7      , 
suggesting that an additional E3 ligase can promote ubiqui-
tination of N1-IC. This is consistent with a recent report of 
an FBW7  –  independent destabilizing element in the PEST 
domain (  28  ). These experiments identify a conserved FBW7 
degron in the N1-IC PEST domain and demonstrate its abil-
ity to alter NOTCH1 signaling. 
  Molecular analysis of the NOTCH1 FBW7 degron 
  FBW7 degrons in most other substrates contain a serine resi-
due at the T 4 position. Welcker et al. have demonstrated 
potential degrons in N1-IC that could be targeted by FBW7. 
One site fell outside of the PEST domain (T  2133  ), but was 
chosen because it was previously suggested as a potential 
GSK3-      phosphorylation site and FBW7 degron (  18  ). The 
other three sites were within the PEST domain and included 
two potential phosphorylation sites for a proline-directed 
kinase (T  2484   and T  2512  ) and one nonproline-directed site 
(T  2467  ). We generated four N1-IC constructs, in which one 
of these threonines was replaced with alanine (N1-IC  T2133A  , 
N1-IC  T2467A  , N1-IC  T2484A  , and N1-IC  T2512A  ), and tested each 
one  ’  s ability to interact with DN FBW7. Of the four mu-
tants, only N1-IC  T2512A   failed to coimmunoprecipitate with 
DN FBW7, suggesting that the N1-IC degron recognized by 
FBW7 depends on phosphorylation of T  2512   (  Fig. 2 A  ).   
  Next, we verifi  ed the functionality of these results us-
ing transcriptional reporter assays. In contrast to N1  L1601P  , 
FBW7      failed to suppress the activation of a NOTCH1-
dependent luciferase reporter by N1  L1601P   that also contained 
a T2512A substitution (N1  L1601P-T2512A  ;   Fig. 2 B  ). Further-
more, DN FBW7 was unable to augment NOTCH1 activa-
tion induced by that construct in Bosc23 cells (unpublished 
data). Thus, mutation of a single residue (T  2512  ) could reca-
pitulate the eff  ects of a      PEST mutation in this specifi  c assay. 
Finally, we have previously hypothesized that loss of FBW7  –
  NOTCH1 interactions could be a mechanism for enhancing 
NOTCH1-dependent transcriptional induction. To address 
this issue, we compared the activity of each mutant and found 
  Figure 3.     FBW7 mutations in T-ALL preclude interaction with NOTCH1, c-Myc, and cyclin E. (A) Schematic depiction of the positions of the 
FBW7 binding pocket and DN FBW7. (B) Chromatograms showing mutations of FBW7 R  465   and  R 505   found in CEM and P12-ICHIKAWA T-ALL cell lines. 
DND41 cells express WT FBW7. Arrows indicate mutated nucleotides. (C) Coimmunoprecipitation experiments demonstrating the inability of DN 
FBW7  R465C  , DN FBW7  R479Q  , and DN FBW7  R505C   to interact with N1-IC. (D and E) The same DN FBW7 mutants as in C do not interact with c-Myc and cyclin E. 
Asterisk in E indicates a nonspecifi   c  band.   JEM VOL. 204, August 6, 2007 
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Although FBW7 mutations underlie a wide variety of solid 
human cancers, it is unknown whether they occur in T-ALL. 
To address this, we sequenced the F-box and WD40 repeat 
regions of   FBXW7   from 13 T-ALL cell lines. We found single-
nucleotide substitutions that resulted in point mutations in 
4 lines (30.8%, Table S1, available at http://www.jem.org/
cgi/content/full/jem.20070872/DC1). We also found that 
one T-ALL line (Be13) does not express any FBW7 message, 
likely because of a chromosomal deletion near the   FBXW7   
locus (  32  ). In addition to the cell lines, we sequenced   FBXW7   
from 95 primary T-ALL patient samples; 15 of these samples 
(16%) carried an FBW7 mutation (  Table I  ).   Further analysis 
revealed that 12% (7/58) of the diagnostic and 22% (8/37) 
of the relapse samples sequenced harbored FBW7 mutations. 
For 7 of those relapse samples, we were able to locate and 
sequence their diagnostic counterparts, and we discovered 
that 4 (57%) of these patients acquired the mutation only at 
relapse (  Table I  ), suggesting that such mutations could serve 
as a mechanism of drug resistance in T-ALL. 
  T-ALL FBW7 mutants lose their ability to bind NOTCH1, 
c-Myc, and cyclin E 
  All of the mutations identifi  ed aff  ected one of three conserved 
arginine residues (R  465  , R  479  , and R  505  ) in WD40 repeats III 
that a negative charge at that position  —  either from a phospho-
serine/threonine or an acidic residue  —  is required for recog-
nition by FBW7 (  29, 30  ). To determine if this is true for 
recognition of NOTCH1 by FBW7, we substituted E  2516   
with either alanine or aspartate (N1-IC  E2516A   and N1-IC  E2516D  , 
respectively). As shown in   Fig. 2 E  , N1-IC  E2516A   was unable 
to bind to DN FBW7; however, we observed partial binding 
with N1-IC  E2516D  . Thus, although glutamate appears to be 
required at T 4 for optimal binding, substituting a nega-
tively charged aspartate at that position permits at least some 
interaction with FBW7. 
  The degron we identifi  ed in N1-IC contains serine-
proline motifs at T 2 and T 5, either of which could be 
targeted by a proline-directed kinase. Indeed, both S  2514   and 
S  2517   have been previously suggested to be CDK8 phosphor-
ylation sites (  31  ). To evaluate their importance for recogni-
tion by FBW7, we generated N1-IC constructs in which one 
or both residues were replaced with alanine (N1-IC  S2514A  , 
N1-IC  S2517A  , and N1-IC  S2514A-S2517A  ). Although mutation of 
S  2517   did not aff  ect binding, mutation of S  2514   impaired it, and 
binding was completely abolished in the N1-IC mutant lack-
ing both residues (  Fig. 2 F  ). These studies demonstrate that 
the FBW7 degron in NOTCH1 requires a conserved charged 
residue and is potentially targeted by CDK8. 
  PEST mutations in primary T-ALL disrupt the FBW7 degron 
  To further test the hypothesis that mutations of the FBW7 
degron (spanning from L  2511   to P  2519  ) could be a mechanism 
that promotes transformation in T-ALL, we have studied 
the pattern of PEST mutations found in T-ALL lines and 
primary tumors (  8  ). PEST mutations appear to be of great 
importance, as they have been found in the majority of 
Notch1-induced T-ALL samples of both human and mouse 
origin. These mutations fell into three categories relative to 
the FBW7 degron. The majority of the mutations introduced 
translational termination codons starting as early as amino 
acid 2342 (sample T-ALL 44), and thus deleting almost the 
entire PEST domain. A second category included mutations 
that introduced termination codons immediately upstream of 
the L  2511   residue (sample T-ALL 63). A third category of at 
least nine identifi  ed mutants included mutations that specifi  -
cally targeted the FBW7 degron (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20070872/DC1). For 
example, the mutant found in the KOPTK1 T-ALL sample 
replaced the WT LTPSPESP degron with a mutated LTP-
SRVP sequence. These fi  ndings support our hypothesis and 
suggest that abrogation of the FBW7-controlled NOTCH1 
degradation is an important transforming event in T-ALL. 
  T-ALL cell lines and primary tumors carry conserved 
FBW7 mutations 
  Our previous observations suggested an   “  indirect  ”   way to 
inactivate FBW7 by deleting the degron on NOTCH1. As 
PEST mutations occur in a fraction of T-ALL tumors, we won-
dered whether selective pressure might exist for these cancers to 
develop FBW7 mutations that abrogate NOTCH1   recognition. 
    Table I.    FBW7 is mutated in a high percentage of primary 
human T-ALL samples 
Patient 
  number
Diagnostic/relapse 
  sample
  FBXW7   sequence 
  NM_033632.2
Predicted 
amino acid 
change
602-783 Diagnosis C1542T R465C
603-932 Diagnosis C1542T R465C
1 Diagnosis NA NA
Relapse C1542T (homozygous) R465C
4 Diagnosis WT WT
Relapse C1542T R465C
17 Diagnosis C1542T R465C
Relapse C1542T R465C
16 Diagnosis G1543A R465H
Relapse G1543A R465H
602-455 Diagnosis G1543A R465H
601-268 Diagnosis G1543A R465H
27 Diagnosis WT WT
Relapse G1543A R465H
4451 Diagnosis G1585A R479Q
602-839 Diagnosis G1585A R479Q
603-473 Diagnosis G1585A R479Q
29 Diagnosis C1662T R505C
Relapse C1662T R505C
22 Diagnosis WT WT
Relapse C1662T R505C
35 Diagnosis WT WT
Relapse G1663T R505L1830 FBW7 MUTATIONS IN T CELL LEUKEMIA | Thompson et al.
on the   FBW7   gene. They also suggested that an FBW7 muta-
tion could be a mechanism of signal amplifi  cation for the 
NOTCH1-HD mutants that are weak transcriptional activa-
tors. This scenario was supported by our reporter analysis 
shown in   Fig. 2 C  , where introduction of a T  2512   mutation 
abolishes FBW7 binding and induces a fi  vefold increase in 
NOTCH1 transcriptional activation. To further prove this 
hypothesis, we have sequenced the   NOTCH1   locus in the 
previously described cohort of primary T-ALL patient samples. 
As evident from   Table II  , almost 43% (38/89) of the patient 
samples harbored NOTCH1 mutations.   In agreement with 
our previous observations, none of the FBW7  mut   samples 
(0/15) had a PEST mutation. On the other hand, 60% (9/15) 
of the FBW7  mut   samples had NOTCH1-HD mutations. The 
remaining 40% of the FBW7  mut   samples had no NOTCH1 
mutations. These results suggested that cooperation of FBW7 
and NOTCH1 mutations can be found in a substantial frac-
tion of T-ALL, and could be critical for disease progression 
and treatment outcome. 
  Restoration of FBW7 function decreases activation 
of the NOTCH1 pathway 
  If our hypothesis that FBW7 mutations in T-ALL lines con-
tribute to NOTCH1-induced transformation is correct, then 
restoration of FBW7 expression should suppress NOTCH1 
pathway activation in these cells. We thus used retroviral 
gene transfer to restore WT FBW7      expression in mutant 
T-ALL lines. Our initial observations, using both RT-PCR 
and immunofl  uorescence detection, was that Flag-FBW7      
and IV of FBW7 (  Table I   and   Fig. 3, A and B  ).   These three 
residues (  Fig. 3 A  ) comprise the binding pocket of FBW7 
that permits substrate recognition, and all of them contact the 
phosphothreonine in the consensus degron (  33  ). Nash et al. 
have shown that mutations of any of these three arginine res-
idues prevent yeast Cdc4 from associating with cyclin E (  34  ). 
To determine whether the NOTCH1 degron is recognized 
by FBW7 in the same manner, we generated DN FBW7 
mutants in which R  465  , R  479  , or R  505   was replaced with cys-
teine (DN FBW7  R465C   and DN FBW7  R505C  ) or glutamine 
(DN FBW7  R479Q  ) and tested their abilities to interact with 
N1-IC. We chose these substitutions because they recapit-
ulated FBW7 mutations found in our T-ALL samples. All 
three FBW7 mutants failed to bind (  Fig. 3 C  ) and ubiqui-
tinate (not depicted) N1-IC. They also failed to bind to two 
other characterized FBW7 substrates, c-Myc and cyclin E 
(  Fig. 3, D and E  ). 
  Analysis of the mutational status of the NOTCH1 locus 
in FBW7 mutants 
  Interestingly, subsequent analysis of the   NOTCH1   locus 
demonstrated that none of the T-ALL lines bearing FBW7 
mutations (0/5) had any NOTCH1 PEST mutations. Indeed, 
all of them had either NOTCH1-HD mutations (RPMI 8402, 
P12-ICHIKAWA, and CEM) or expressed WT NOTCH1 
alleles (Be13 and Jurkat E6). Furthermore, all sequenced 
T-ALL lines carrying NOTCH1 PEST mutations expressed 
WT FBW7. These observations (Table S1) suggested that a 
NOTCH1 PEST mutation relieves the mutational   “  pressure  ”   
  Figure 4.     Restoration of FBW7 expression in CEM cells (FBW7  MUT  ) suppresses NOTCH1 target genes. (A and B) Effi  cient restoration of FBW7  WT  
in CEM T-ALL cells after transduction with a Flag-FBW7     – expressing  retrovirus  (MigR1-FBW7    ). Cells were infected with empty MigR1 vector as a con-
trol. (A) RT-PCR amplifi  ed Flag-FBW7      only in cells infected with MigR1-FBW7     . (B) Immunofl  uorescence staining of FACS-sorted CEM cells infected 
with MigR1-FBW7      using FITC-conjugated anti-Flag antibody shows nuclear localization of the construct. (C) Real-time RT-PCR was used to quantify 
the expression of the NOTCH1 target genes,   DELTEX1  , and   HES1   in CEM cells infected as in A Infection with MigR1-FBW7      suppressed the two genes 
(P       0.0001 for both). Error bars represent the SD of triplicate wells.     JEM VOL. 204, August 6, 2007 
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    Table II.    Notch1 mutational analysis of the primary T-ALL patient samples 
Patient # Notch1 FBW7 Patient # Notch1 FBW7
600  –  929 WT WT 13a WT WT
601  –  039 PEST WT 14a WT WT
601  –  068 PEST WT 15a TAD WT
601  –  268 HD exon 26 R465H 16a HD, exon 26 R465H
601  –  301 PEST WT 17a HD, exon 26 R465C
601  –  464 WT WT 18a WT WT
601  –  705 WT WT 19a WT WT
601  –  756 HD exon 26, TAD WT 20a TAD WT
1601  –  967 WT WT 21a WT WT
1601  –  991 WT WT 22a HD, exon 26 R505C
602  –  214 WT WT 26a HD, exon 26 WT
602  –  317 PEST WT 27a WT R465H
602  –  455 WT R465H 28a PEST WT
602  –  465 HD exon 26 WT 29a HD, exon 26 R505C
602  –  774 TAD WT 30a WT WT
602  –  787 HD exon 26 R465C 31a HD, exon 26 WT
602  –  818 HD exon 26, PEST WT 33a WT WT
602  –  839 HD exon 27 R479Q 34 PEST WT
603  –  007 HD exon 26, PEST WT 34a HD, exon 26, PEST WT
603  –  118 WT WT 35 WT WT
603  –  194 HD exon 26 WT 35a HD, exon 26 R505L
603  –  473 WT R479Q 37a WT WT
603  –  824 WT WT 38a WT WT
603  –  825 WT WT 39a WT WT
603  –  885 PEST WT 40a WT WT
603  –  888 WT WT 41a WT WT
603  –  895 WT WT 42a WT WT
603  –  932 WT R465C 600  –  361 WT WT
603  –  082 PEST WT 600  –  619 WT WT
604  –  099 WT WT 600  –  745 WT WT
604  –  198 WT WT 600  –  971 HD, exon 27 WT
604  –  436 WT WT 600  –  484 PEST WT
604  –  580 WT WT 602  –  819 PEST WT
604  –  618 PEST WT 603  –  829 WT WT
1a HD, exon 26 R465C 600  –  903 WT WT
2a WT WT 2629 WT WT
3a PEST WT 8192 WT WT
4a WT R465C 8024 HD, exon 26 WT
5a WT WT 5833 WT WT
6a PEST WT 5182 WT WT
7a WT WT 747 PEST WT
8a WT WT 4451 WT R479Q
9a PEST WT 16a HD, exon 26 R465H
10a WT WT 17a HD, exon 26 R465C
11a WT WT 18a WT WT
12a WT WT 19a WT WT
PEST, HD, and TAD denote the NOTCH1 domains where the mutations are located.1832 FBW7 MUTATIONS IN T CELL LEUKEMIA | Thompson et al.
degradation. We demonstrate that FBW7 targets NOTCH1 
for ubiquitination and map in detail the amino acid degron 
sequence required for this interaction. Furthermore, we 
identify inactivating FBW7 mutations in     40% of human 
T-ALL lines and 16% of primary leukemias. These muta-
tions abolish the ability of FBW7 to interact with its targets, 
including NOTCH1, c-Myc, and cyclin E. 
  Initially, using a series of amino acid point mutants, we 
have mapped the N1-IC  –  FBW7 interaction to a degron cen-
tered around T  2512  . We further analyzed the degron, demon-
strating that a T 4 acidic glutamate is necessary for interaction 
with FBW7. The reason for this requirement is not clear. 
Possibly, a negative charge at position 2516 either facilitates 
the phosphorylation of T  2512   or directly promotes interaction 
with FBW7. Current evidence suggests that phosphorylation 
of N1-IC by CDK8 plays a key role in recognition by FBW7. 
Work by Fryer et al. showed that MAML1 recruits CDK8 to 
the N1-IC transcriptional activation complex, and this kinase 
phosphorylates N1-IC to promote its degradation (  31  ). Two 
of the three CDK8 phosphorylation sites reported in that 
study are within the T  2512   degron we identifi  ed. Although 
mutation of either S  2514   or S  2517   by itself allowed at least some 
interaction with FBW7 (albeit compromised in the case of 
S  2514  ), a N1-IC with both residues mutated lost all ability 
to bind FBW7. Together with the work of Fryer et al., our 
observations suggest that CDK8 must phosphorylate N1-IC 
(minimally at S  2514  ) for it to be effi   ciently recognized by 
FBW7, either by priming the site for a diff  erent kinase that 
phosphorylates T  2512  , or by directly facilitating physical inter-
action with FBW7. We do not know the identity of the 
kinase that phosphorylates T  2512  ; CDK8 might be respon-
sible for this, too, but that possibility has not been directly 
tested. Although the N1-IC degron identifi  ed here is both 
similar to and diff  erent from degrons in other FBW7 substrates, 
was effi   ciently expressed and had a characteristic nuclear lo-
calization (  Fig. 4, A and B  ).   To directly connect targeting of 
the NOTCH1 pathway by FBW7, we quantifi  ed the expres-
sion of two well-characterized direct transcriptional targets of 
NOTCH1,   HES1   and   DELTEX1   (  17  ). As shown by real-
time RT-PCR experiments (  Fig. 4 C  ), expression of both 
genes was signifi  cantly (P   <   0.001) decreased upon FBW7 
expression. These observations demonstrate that restoration of 
FBW7 expression specifi  cally targets the NOTCH1 pathway 
in T-ALL cells. 
  c-Myc stabilization in FBW7  MUT   as a mechanism 
of resistance to     -secretase inhibition 
  In line with the hypothesis that FBW7 mutations could be a 
novel mechanism of treatment resistance, we have seen that 
all T-ALL lines (5/5) bearing FBW7 mutations were resistant 
to treatment with      -secretase inhibitors (GSIs; unpublished 
data) (  8  ). The most attractive mechanism of resistance was 
the stabilization of c-Myc, as   c-Myc   was previously shown to 
be a direct target of NOTCH1 activation (  16  –  18  ). Thus, we 
decided to study the regulation of c-Myc in T-ALL lines that 
bear FBW7 mutations. Initially, to demonstrate that c-Myc is 
regulated by FBW7 in T-ALL, we have shown that the mu-
tated FBW7 proteins fail to interact with c-Myc (  Fig. 3, 
D and E  ). Moreover, treatment of WT FBW7 (FBW7  WT  ) T-
ALL lines with the proteasome inhibitor MG132 for 6 h re-
sulted in the accumulation of c-Myc caused by the inhibition 
of SCF  FBW7  -mediated proteolysis. On the other hand, similar 
treatment of mutant FBW7 (FBW7  MUT  ) T-ALL lines showed 
no c-Myc protein accumulation (  Fig. 5 A  ).   To directly ad-
dress the mechanism of      -secretase inhibitor resistance in 
the FBW7  MUT   T-ALL lines, we treated KOPTK (FBW7  WT  ), 
Be13 (FBW7  MUT  ), P12-ICHICAWA (FBW7  MUT  ), and CEM 
(FBW7  MUT  ) cells with      -secretase inhibitor (Compound E) 
for 1  –  4 d. As shown in   Fig. 5 B  , N1-IC protein expression 
was drastically and rapidly down-regulated in all four lines 
because the inhibition of      -secretase  –  mediated cleavage. c-Myc 
protein declined after 1 d of Compound E treatment in KOPTK 
(FBW7  WT  ) cells (note the     2-fold increase in protein loading 
in days 1  –  4 compared with day 0). In contrast, c-Myc protein 
levels remained stable in the 3 FBW7  MUT   lines during the 4 d 
of treatment. Together, these studies suggest that blocking 
NOTCH1 signaling alone cannot down-regulate c-Myc pro-
tein expression in the context of a coexisting FBW7 mutation. 
As a result, FBW7-inactivating mutations could provide an 
  “  escape  ”   mechanism for GSI-treated T-ALLs caused by the 
stabilization of c-Myc. 
    DISCUSSION   
  The discovery that hyperactivation of the NOTCH1 path-
way contributes to the majority of T-ALL cases revolution-
ized both scientifi  c and clinical perspectives in this fi  eld, and 
has spurred a search for NOTCH1-silencing therapeutic agents. 
At the core of this search is the need for a more complete 
understanding of NOTCH1 protein stability regulation, as 
the majority of the mutations aff  ect proteasome-mediated 
  Figure 5.     FBW7 mutations as a mechanism of resistance to 
     -secretase inhibition. (A) T-ALL cell lines were treated with MG132 
(20      M for 6 h) and analyzed for expression of c-Myc and actin. Treatment 
with MG132 resulted in accumulation of c-Myc in KOPTK cells, which 
express WT FBW7, but not in Be13 and P12-ICHIKAWA cells, which ex-
press no and mutant FBW7, respectively. (B) Expression of N1-IC and 
c-Myc after treatment with Compound E (CompE) for 1  –  4 d. c-Myc 
expression declines only in KOPTK1 cells, which are sensitive to this treat-
ment, but not in Be13 and P12-ICHIKAWA cells, which are resistant. 
N1-IC expression decreased in all of the cell lines, refl  ecting inhibition of 
     -secretase  –  mediated cleavage of NOTCH1. Actin expression was used as 
a loading control for both A and B.     JEM VOL. 204, August 6, 2007 
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all T-ALL lines carrying FBW7 mutations were resistant to 
treatment with GSI. FBW7 is a very attractive treatment re-
sistance candidate because of its ubiquitin ligase function and its 
ability to target c-Myc protein stability. c-Myc is a direct tran-
scriptional target of NOTCH1, and overexpression of c-Myc 
can rescue most T-ALL lines treated with GSI (  16  –  18, 39  ). 
As c-Myc is a posttranslational target of FBW7 (  40  ), but  —  at 
the same time  —  a transcriptional target of NOTCH activ-
ity (  16  –  18  ), the transforming ability of FBW7 inactivation 
could be twofold; by losing FBW7 function, a cell should not 
only stabilize c-Myc but also produce more of it because of 
increased NOTCH1 signaling. In agreement with this hypo-
thesis, we have shown that T-ALL FBW7 mutants lose their 
ability to recognize c-Myc. Also, our experiments demon-
strate that c-Myc protein remains stable upon GSI treatment 
of lines carrying FBW7 inhibitors. Although these experi-
ments strongly argue for a role for FBW7, further experi-
mentation, preferably in vivo, is required to prove the role of 
FBW7 defi  ciency in GSI resistance. Moreover, it is possible 
that there are multiple resistance mechanisms, as we have 
found that a T-ALL line (PF382) was FBW7  WT  , yet resistant 
to GSI treatment. 
  We report the identifi  cation of FBW7 mutations in hu-
man T-ALL and their direct connection to the NOTCH1  –
  c-Myc oncogenic pathway caused by the ability of FBW7 
to recognize, bind, and ubiquitinate these target proteins. 
These mutations target conserved arginines that form the 
binding pocket of FBW7 and abolish its binding to its targets. 
We believe that the identifi  cation of FBW7 mutations is 
of unique importance for the design of future molecular 
therapies for T-ALL. Indeed, our data suggest that these 
treatments should be multifaceted, covering both NOTCH1 
activation and potential escape mechanisms, such as FBW7 
mutations, and their eff  ects on the stability of downstream 
target proteins. 
    MATERIAL AND METHODS   
    FBW7 and NOTCH1 mutational analysis.     Genomic DNA extracted 
from cryopreserved lymphoblast samples provided by collaborating institu-
tions in the United States (St. Jude Children  ’  s Research Hospital, Memphis, 
TN) and Canada (Hospital for Sick Children, Toronto, Canada). Analysis 
of FBW7 mutations in DNA samples from paired diagnostic and relapse 
T-ALLs was performed in samples from patients enrolled in Associazione 
Italiana Ematologia Oncologia Pediatrica  –  Berlin-Frankfurt-Munster Study 
Group protocols (  41  ). 
    Recombinant DNA constructs and retrovirus production.     Expres-
sion vectors carrying Flag-tagged NOTCH1, NOTCH1  L1601P-     82  , and 
NOTCH1  L1601P-T2512A   mutants were created by multistep insertion of PCR-
amplifi  ed human NOTCH1 sequences into pcDNA3.1 (Invitrogen). The 
     PEST mutants (     82 and      162) were generated by PCR and cloned into 
the pCS2-N1-IC HA. The Flag-tagged FBW7      and DN FBW7 expression 
plasmids were a gift from B. Clurman (Fred Hutchinson Cancer Research 
Center, Seattle, WA); the cyclin E, Ub-HA, and SCF (CUL1, ROC1, and 
SKP1) mammalian expression vectors were gifts from M. Pagano (New York 
University, New York, NY). The Flag-tagged DN FBW7 and N1-IC HA 
point mutants were generated by site-directed mutagenesis following the 
manufacturer  ’  s protocol (Stratagene). Integrity of all constructs was verifi  ed 
by sequencing and protein expression was confi  rmed by Western blotting. 
it appears to occupy the canonical FBW7-binding pocket. 
Crystal structures of Cdc4 bound to a cyclin E peptide show 
that the phospho-T in the degron makes physical contact 
with three arginine residues, R  465  , R  479  , and R  505  , in WD40 
repeats III and IV (numbering based on FBW7      isoform) (  33  ). 
We have found that the FBW7 point mutations identifi  ed in 
T-ALL cell lines and primary leukemia aff  ect these arginine 
residues, which is consistent with fi  ndings in solid human 
tumors (  35, 36  ). It has been suggested that Fbw7 is a haploin-
suffi   cient tumor suppressor in p53   /  −    mice (  37  ), which supports 
the idea that decreased gene dosage stabilizes FBW7 targets in 
vivo. However, it is also possible that these mutations act as 
DNs because their inabilities to interact with the NOTCH1 
and c-Myc degrons might create a pool of nonfunctional 
SCF  FBW7   complexes. 
  Although previously detected in certain solid tumors, 
FBW7-inactivating mutations do not appear to be a general 
oncogenic trigger in leukemia. Indeed, a recent sequencing 
of a large number of acute myeloid leukemia (AML) patient 
samples failed to detect any such mutations (  38  ). Thus, it was 
a surprise to detect FBW7-inactivating mutations in both 
T-ALL lines and primary T-ALL samples. These findings 
suggested that FBW7 mutations could be frequent in T-ALL 
because of the ability of FBW7 to recognize, bind to, and 
degrade important oncogenes, including N1-IC and its tran-
scriptional target c-Myc. Interestingly, it seems that FBW7 
defi  ciency could either activate the NOTCH pathway in 
the absence of NOTCH1 mutations or amplify its signaling 
strength by cooperating with already existing NOTCH1-HD 
mutations. If loss of FBW7 is, indeed, a NOTCH1 signal 
amplifi  er that facilitates NOTCH1-induced transformation, 
one would predict that selective pressure to acquire an FBW7 
mutation preferentially aff  ects lymphocytes in which the 
NOTCH1 PEST domain remains intact, as no increase in 
NOTCH1 signaling capacity could be gained by eliminating 
FBW7 function in the context of an existing PEST deletion. 
In agreement with this hypothesis, none of the 13 T-ALL cell 
lines or 96 primary samples showed any coexisting FBW7 
and NOTCH1 PEST mutations. On the other hand, 60% 
of FBW7  mut   samples had mutations in the NOTCH1-HD 
domain. These results suggest that, in T-ALL, the selective 
pressure to increase NOTCH1 stability and signaling strength 
is a primary force that drives oncogenesis. However, we do not 
want to imply that FBW7-mediated transformation depends 
solely on NOTCH1 activation. Both c-Myc and cyclin E 
could also be the mediators of this process. However, c-Myc 
is also a direct target of NOTCH signaling, so it is possible 
that FBW7 could impinge on both signaling pathways. The 
specifi  c contribution and the importance of each FBW7 tar-
get in the induction of T-ALL remains to be analyzed using 
in vivo genetic approaches. 
  Moreover, we found that FBW7 mutations were more 
frequent in relapse samples and that more than half of the 
patients with FBW7 mutations at relapse did not carry the 
mutation at diagnosis, suggesting that FBW7 mutation might 
be an event that confers resistance to treatment. Interestingly, 1834 FBW7 MUTATIONS IN T CELL LEUKEMIA | Thompson et al.
with 4,6-diamidino-2-phenylindole, and treated with a prolonged antifading 
medium (Invitrogen). Images were acquired on a confocal station (Leica) 
and analyzed using ImageJ (National Institutes of Health) software. 
  Luciferase assays.     Bosc23 or HeLa cells cultured at 37  °  C under 5% CO  2   in 
IMDM supplemented with 10% FBS, penicillin, and streptomycin were 
seeded on 24-well plates at 8       10  4   cells per well and transiently transfected 
with expression constructs using FuGENE 6 Transfection Reagent (Roche), 
according to the manufacturer  ’  s protocols. Equivalent DNA concentrations 
were maintained by adding the appropriate amounts of pCDNA3.1 vector. 
Whole-cell lysates were prepared 48 h after transfection, and luciferase activity 
was determined using a Dual-Luciferase Reporter Assay System (Promega). 
  Online supplemental material.     Table S1 shows that FBW7 mutations are 
only present in human T-ALL cell lines with HD mutations or WT NOTCH1. 
Fig. S1 shows a comparative analysis of NOTCH1 PEST domain mutations 
found in human T-ALL lines and patients. The online version of this article is 
available at http://www.jem.org/cgi/content/full/jem.20070872/DC1. 
  We would like to thank Michele Pagano, Piers Nash, William Carroll, Elizabeth Raetz, 
and Jane Skok for discussions and technical guidance. We also thank Bruce Clurman 
and Tasuku Honjo for sharing materials, and Mark Minden and A. Thomas Look for 
valuable clinical samples and communicating unpublished results. 
  This work was supported by the Fondazione Citt  à   Della Speranza (G. Basso), 
the WOLF Foundation (A. Ferrando), and National Institutes of Health (NIH) grant 
CA120196 (A. Ferrando). I. Aifantis is supported by the Cancer Research Institute, 
the Sidney Kimmel Foundation for Cancer Research, the G  &  P Foundation for Cancer 
Research, the Penelope London Fund, the Friedman Fund for Childhood Leukemia, 
and NIH grant R01CA105129. S. Buonamici is supported by the New York University 
Molecular Oncology and Immunology Training grant. A. Ferrando is a Leukemia and 
Lymphoma Society Scholar. 
  The authors declare that they have no competing interests 
Submitted:   1 May 2007 
Accepted:   28 June 2007 
  REFERENCES 
       1  .   Grabher  ,   C.  ,   H.     von Boehmer  , and   A.T.     Look  .   2006  .   Notch 1 activation 
in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.   
    Nat. Rev. Cancer    .   6  :  1    –    13  .   
       2  .   Artavanis-Tsakonas  ,   S.  ,   M.D.     Rand  , and   R.J.     Lake  .   1999  .   Notch sig-
naling: cell fate control and signal integration in development.       Science    . 
  284  :  770    –    776  .   
       3  .   Radtke  ,   F.  ,   F.     Schweisguth  , and   W.     Pear  .   2005  .   The Notch   ‘  gospel  ’  .   
    EMBO Rep.       6  :  1120    –    1125  .   
       4  .   Maillard  ,   I.  ,   T.     Fang  , and   W.S.     Pear  .   2005  .   Regulation of lymphoid 
development, diff  erentiation, and function by the notch pathway.       Annu. 
Rev. Immunol.       23  :  945    –    974  .   
       5  .   Rothenberg  ,   E.V.  , and   T.     Taghon  .   2005  .   Molecular genetics of T cell 
development.       Annu. Rev. Immunol.       23  :  601    –    649  .   
       6  .   Radtke  ,   F.  ,   A.     Wilson  ,   G.     Stark  ,   M.     Bauer  ,   J.     van Meerwijk  ,   H.R.   
  MacDonald  , and   M.     Aguet  .   1999  .   Defi  cient T cell fate specifi  cation in 
mice with an induced inactivation of Notch1.       Immunity    .   10  :  547    –    558  .   
       7  .   Ciofani  ,   M.  , and   J.C.     Zuniga-Pfl  ucker  .   2005  .   Notch promotes survival 
of pre-T cells at the beta-selection checkpoint by regulating cellular 
metabolism.       Nat. Immunol.       6  :  881    –    888  .   
       8  .   Weng  ,   A.P.  ,   A.A.     Ferrando  ,   W.     Lee  ,   J.P.     Morris     IV  ,   L.B.     Silverman  , 
  C.     Sanchez-Irizarry  ,   S.C.     Blacklow  ,   A.T.     Look  , and   J.C.     Aster  .   2004  . 
  Activating mutations of NOTCH1 in human T cell acute lymphoblastic 
leukemia.       Science    .   306  :  269    –    271  .   
       9  .   Reschly  ,  E.J.  ,  C.    Spaulding  ,  T.    Vilimas  ,  W.V.    Graham  ,  R.L.    Brumbaugh  , 
  I.     Aifantis  ,   W.S.     Pear  , and   B.L.     Kee  .   2006  .   Notch1 promotes survival of 
E2A-defi  cient T cell lymphomas through Pre-T cell receptor dependent 
and independent mechanisms.       Blood    .   107  :  4115    –    4121  .   
        10  .   Dumortier  ,   A.  ,   R.     Jeannet  ,   P.     Kirstetter  ,   E.     Kleinmann  ,   M.     Sellars  , 
  N.R.     dos Santos  ,   C.     Thibault  ,   J.     Barths  ,   J.     Ghysdael  ,   J.A.     Punt  ,   et al  . 
  2006  .   Notch activation is an early and critical event during T-cell leuke-
mogenesis in Ikaros-defi  cient mice.       Mol. Cell. Biol.       26  :  209    –    220  .   
  Retroviral supernatants were generated as previously described (  42  ), 
concentrated by 2.5 h centrifugation at 16,500 rpm, and resuspended in 
    200      l of serum-free medium. 
  Western blot and coimmunoprecipitation.     Bosc23 cells were plated in 
6-cm plates and transfected with expression plasmids using FuGENE 6 
Transfection Reagent, according to the manufacturer  ’  s protocols (Roche). 
Cells were lysed using TENT buff  er (50 mM Tris pH 8, 150 mM NaCl, 
2 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 mM NaF, 1 mM Na  3  VO  4  , 
and 0.2% protease inhibitor cocktail [Sigma-Aldrich]). Total cell extracts 
were incubated with HA or Flag beads and rocked for 1 h at 4  °  C. Bead-
bound proteins were collected by centrifugation, and after being washed 
three times they were loaded in 8% SDS-based gels and analyzed by Western 
blotting using Flag M2 (Sigma-Aldrich), HA probe (Santa Cruz Biotechnol-
ogy), and Notch1 (C20; Santa Cruz Biotechnology) antibodies. The T-ALL 
lines cultured at 37  °  C under 5% CO  2   in RPMI 1640 supplemented with 
10% FBS, penicillin, and streptomycin were lysed using TENT buff  er after 
incubation with 1      M Compound E or 20      M MG132, as specifi  ed in the 
text. Total cell lysates were loaded and run in 12% SDS gels and analyzed by 
Western blot using antibody against Notch1 Val1744 (Cell Signaling Tech-
nology), c-Myc (N-262; Santa Cruz Biotechnology), cyclin E (HE12; Santa 
Cruz Biotechnology), and actin (CHEMICON International, Inc.). 
  RT-PCR, sequencing, and real-time RT-PCR analysis.     Total cellular 
RNA treated with DNaseI was extracted as described in the QIAGEN hand-
book (QIAGEN). cDNA was prepared according to the First Strand cDNA 
Synthesis kit protocol (Invitrogen). RT-PCR was performed in 25-    l reactions 
containing 1.5      l cDNA, 1      l   Taq   Red DNA Polymerase (Sigma-Aldrich), 
and 200 nM forward and reverse primers. For detection of Flag-FBW7     , 
the following primers were used:   Flag   forward 5     -TACAAGGATGACGAT-
GACAAGC-3      and   FBW7        reverse 5     -CACTCTCCTGGTCCATCTCC-3     . 
For sequencing of FBW7 in human T-ALL lines,     1.2 kb of cDNA that 
encodes the FBW7 F-box and WD40 repeats domains was amplifi  ed using 
the FastStart High Fidelity PCR kit (Roche) according to manufacturer  ’  s 
instructions, using the following primers:   FB2   forward 5     -AACAACTTTT-
GGGGACCTC-3      and   WD1   reverse 5     -ACACAACTCCCCCACTCCC-3     . 
PCR products were run on 1% Agarose gels, and the appropriate ampli-
con was purifi  ed and sent for direct bidirectional sequencing with the same 
primers. Sequencing of FBW7 from primary human samples was done by 
amplifying exons 9 and 10 from genomic DNA with the following primers: 
  exon 9   forward 5     -TGATGGGATCATTTTATACGGATG-3     ,   exon 9   
reverse 5     -GACAAAACGCTATGGCTTTCC-3     ,   exon 10   forward 5     -CCC-
AACTTCCCATTCCCTTA-3     , and   exon 10   reverse 5     -TTTCTTCAT-
GCCAATTTTAACG-3     . The amplicon was sequenced with the following 
primers:   exon 9se  q forward 5     -TTTAAATCACTTTTCCTTTCTACCC-3      
and   exon 10seq   forward 5     -TGACTAAATCTACCATGTTTTCTCA. 
Quantitative RT-PCR was performed in a 50-     l reaction containing 2      l 
of cDNA, 12.5      l of the SYBR Green SuperMix (Bio-Rad Laboratories), 
200 nM forward and reverse primers. Real-time RT-PCR amplifi  cation was 
performed on the iCycler iQ detection system, and the data were collected 
and analyzed using iCycler iQ version 3.1 software (Bio-Rad Laboratories). 
The primers used were as follows:   DELTEX1   forward 5     -TGGTCACAG-
CATCAGGCTAC-3      and   DELTEX1   reverse 5     -TGGTCTGGGTAT-
CAGGGAAG-3     ;   HES1   forward 5     -TGAGCCAGCTGAAAACACTG-3      
and   HES1   reverse 5     -CATTGATCTGGGTCATGCAG-3     ; and   ACTIN   
forward 5     -TCGTGCGTGACATTAAGGAG-3      and   ACTIN   reverse 
5     -AGC  ACTGTGTTGGCGTACAG-3     . 
  Immunofl  uorescence analysis.     The CEM T-ALL line cells infected with 
FBW7      were washed three times with PBS and fi  xed in 4% paraformalde-
hyde in PBS for 15 min. The cell membrane was permeabilized by treatment 
with 0.5% Triton X-100 for 12 min. The cells were washed with PBS, and 
nonspecifi  c antibody binding was blocked with 5% bovine serum albumin 
(Sigma-Aldrich). The cells were treated with anti  –  Flag-FITC antibody (Sigma-
Aldrich) diluted 1:100 for 1 h. After washing with PBS, the cells were stained JEM VOL. 204, August 6, 2007 
ARTICLE
1835
        11  .   Lin  ,   Y.W.  ,   R.A.     Nichols  ,   J.J.     Letterio  , and   P.D.     Aplan  .   2006  .   Notch1 
mutations are important for leukemic transformation in murine models 
of precursor-T leukemia/lymphoma.       Blood    .   107  :  2540    –    2543  .   
        12  .   O  ’  Neil  ,   J.  ,   J.     Calvo  ,   K.     McKenna  ,   V.     Krishnamoorthy  ,   J.C.     Aster  , 
  C.H.     Bassing  ,   F.W.     Alt  ,   M.     Kelliher  , and   A.T.     Look  .   2006  .   Activating 
Notch1 mutations in mouse models of T-ALL.       Blood    .   107  :  781    –    785  .   
      13  .   Shin  ,   H.M.  ,   L.M.     Minter  ,   O.H.     Cho  ,   S.     Gottipati  ,   A.H.     Fauq  ,   T.E.     Golde  , 
  G.E.     Sonenshein  , and   B.A.     Osborne  .   2006  .   Notch1 augments NF-kappaB 
activity by facilitating its nuclear retention.       EMBO J.       25  :  129    –    138  .   
        14  .   Vilimas  ,   T.  ,   J.     Mascarenhas  ,   T.     Palomero  ,   M.     Mandal  ,   S.     Buonamici  ,   F.   
  Meng  ,   B.     Thompson  ,   C.     Spaulding  ,   S.     Macaroun  ,   M.L.     Alegre  ,   et al  . 
  2006  .   Targeting the NF-kappaB signaling pathway in Notch1-induced 
T-cell leukemia  .     Nat. Med.       13  :  70    –    77     
        15  .   Vilimas  ,   T.  ,   J.     Mascarenhas  ,   T.     Palomero  ,   M.     Mandal  ,   S.     Buonamici  ,   F.   
  Meng  ,   B.     Thompson  ,   C.     Spaulding  ,   S.     Macaroun  ,   M.L.     Alegre  ,   et al  . 
  2007  .   Targeting the NF-kappaB signaling pathway in Notch1-induced 
T-cell leukemia.       Nat. Med.       13  :  70    –    77  .   
        16  .   Weng  ,   A.P.  ,   J.M.     Millholland  ,   Y.     Yashiro-Ohtani  ,   M.L.     Arcangeli  ,   A.   
  Lau  ,   C.     Wai  ,   C.     Del Bianco  ,   C.G.     Rodriguez  ,   H.     Sai  ,   J.     Tobias  ,   et al  . 
  2006  .   c-Myc is an important direct target of Notch1 in T-cell acute 
lymphoblastic leukemia/lymphoma.       Genes Dev.       20  :  2096    –    2109  .   
        17  .   Palomero  ,   T.  ,   W.K.     Lim  ,   D.T.     Odom  ,   M.L.     Sulis  ,   P.J.     Real  ,   A.   
  Margolin  ,   K.C.     Barnes  ,   J.     O  ’  Neil  ,   D.     Neuberg  ,   A.P.     Weng  ,   et al  .   2006  . 
  NOTCH1 directly regulates c-MYC and activates a feed-forward-loop 
transcriptional network promoting leukemic cell growth.       Proc. Natl. 
Acad. Sci. USA    .   103  :  18261    –    18266  .   
        18  .   Klinakis  ,   A.  ,   M.     Szabolcs  ,   K.     Politi  ,   H.     Kiaris  ,   S.     Artavanis-Tsakonas  , 
and   A.     Efstratiadis  .   2006  .   Myc is a Notch1 transcriptional target and 
a requisite for Notch1-induced mammary tumorigenesis in mice.       Proc. 
Natl. Acad. Sci. USA    .   103  :  9262    –    9267  .   
        19  .   Hubbard  ,   E.J.  ,   G.     Wu  ,   J.     Kitajewski  , and   I.     Greenwald  .   1997  .   sel-10, a 
negative regulator of lin-12 activity in   Caenorhabditis elegans  , encodes a 
member of the CDC4 family of proteins.       Genes Dev.       11  :  3182    –    3193  .   
        20  .   Nakayama  ,   K.I.  , and   K.     Nakayama  .   2005  .   Regulation of the cell cycle 
by SCF-type ubiquitin ligases.       Semin. Cell Dev. Biol.       16  :  323    –    333  .   
        21  .   Welcker  ,   M.  ,   A.     Orian  ,   J.     Jin  ,   J.E.     Grim  ,   J.W.     Harper  ,   R.N.     Eisenman  , 
and   B.E.     Clurman  .   2004  .   The Fbw7 tumor suppressor regulates glycogen 
synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.   
    Proc. Natl. Acad. Sci. USA    .   101  :  9085    –    9090  .   
        22  .   Wei  ,   W.  ,   J.     Jin  ,   S.     Schlisio  ,   J.W.     Harper  , and   W.G.     Kaelin     Jr  .   2005  . 
  The v-Jun point mutation allows c-Jun to escape GSK3-dependent 
recognition and destruction by the Fbw7 ubiquitin ligase.       Cancer Cell    . 
  8  :  25    –    33  .   
        23  .   Koepp  ,  D.M.  ,  L.K.    Schaefer  ,  X.    Ye  ,  K.    Keyomarsi  ,  C.    Chu  ,  J.W.    Harper  , 
and   S.J.     Elledge  .   2001  .   Phosphorylation-dependent ubiquitination of 
cyclin E by the SCFFbw7 ubiquitin ligase.       Science    .   294  :  173    –    177  .   
        24  .   Gupta-Rossi  ,   N.  ,   O.     Le Bail  ,   H.     Gonen  ,   C.     Brou  ,   F.     Logeat  ,   E.     Six  , 
  A.     Ciechanover  , and   A.     Israel  .   2001  .   Functional interaction between 
SEL-10, an F-box protein, and the nuclear form of activated Notch1 
receptor.       J. Biol. Chem.       276  :  34371    –    34378  .   
        25  .   Oberg  ,   C.  ,   J.     Li  ,   A.     Pauley  ,   E.     Wolf  ,   M.     Gurney  , and   U.     Lendahl  . 
  2001  .   The Notch intracellular domain is ubiquitinated and negatively 
regulated by the mammalian Sel-10 homolog.       J. Biol. Chem.       276  :
  35847    –    35853  .   
        26  .   Tetzlaff    ,   M.T.  ,   W.     Yu  ,   M.     Li  ,   P.     Zhang  ,   M.     Finegold  ,   K.     Mahon  ,   J.W.   
  Harper  ,   R.J.     Schwartz  , and   S.J.     Elledge  .   2004  .   Defective cardiovascular 
development and elevated cyclin E and Notch proteins in mice lacking 
the Fbw7 F-box protein.       Proc. Natl. Acad. Sci. USA    .   101  :  3338    –    3345  .   
        27  .   Tsunematsu  ,   R.  ,   K.     Nakayama  ,   Y.     Oike  ,   M.     Nishiyama  ,   N.     Ishida  ,   S.   
  Hatakeyama  ,   Y.     Bessho  ,   R.     Kageyama  ,   T.     Suda  , and   K.I.     Nakayama  . 
  2004  .   Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation dur-
ing vascular development.       J. Biol. Chem.       279  :  9417    –    9423  .   
        28  .   Chiang  ,  M.Y.  ,  M.L.    Xu  ,  G.    Histen  ,  O.    Shestova  ,  M.    Roy  ,  Y.    Nam  ,  S.C.   
  Blacklow  ,   D.B.     Sacks  ,   W.S.     Pear  , and   J.C.     Aster  .   2006  .   Identifi  cation of 
a conserved negative regulatory sequence that infl  uences the leukemo-
genic activity of NOTCH1.       Mol. Cell. Biol.       26  :  6261    –    6271  .   
      29  .   Welcker  ,   M.  ,   J.     Singer  ,   K.R.     Loeb  ,   J.     Grim  ,   A.     Bloecher  ,   M.     Gurien-West  , 
  B.E.     Clurman  , and   J.M.     Roberts  .   2003  .   Multisite phosphorylation by Cdk2 
and GSK3 controls cyclin E degradation.       Mol. Cell    .   12  :  381    –    392  .   
        30  .   Welcker  ,   M.  , and   B.E.     Clurman  .   2005  .   The SV40 large T antigen con-
tains a decoy phosphodegron that mediates its interactions with Fbw7/
hCdc4.       J. Biol. Chem.       280  :  7654    –    7658  .   
        31  .   Fryer  ,   C.J.  ,   J.B.     White  , and   K.A.     Jones  .   2004  .   Mastermind recruits 
CycC:CDK8 to phosphorylate the Notch ICD and coordinate activa-
tion with turnover.       Mol. Cell    .   16  :  509    –    520  .   
        32  .   Galili  ,   U.  ,   A.     Peleg  ,   Y.     Milner  , and   N.     Galili  .   1984  .   Be13, a human 
T-leukemia cell line highly sensitive to dexamethasone-induced cytolysis.   
    Cancer Res.       44  :  4594    –    4601  .   
        33  .   Orlicky  ,   S.  ,   X.     Tang  ,   A.     Willems  ,   M.     Tyers  , and   F.     Sicheri  .   2003  . 
  Structural basis for phosphodependent substrate selection and orienta-
tion by the SCFCdc4 ubiquitin ligase.       Cell    .   112  :  243    –    256  .   
        34  .   Nash  ,  P.  ,  X.    Tang  ,  S.    Orlicky  ,  Q.    Chen  ,  F.B.    Gertler  ,  M.D.    Mendenhall  , 
  F.     Sicheri  ,   T.     Pawson  , and   M.     Tyers  .   2001  .   Multisite phosphorylation 
of a CDK inhibitor sets a threshold for the onset of DNA replication.   
    Nature    .   414  :  514    –    521  .   
        35  .   Kemp  ,   Z.  ,   A.     Rowan  ,   W.     Chambers  ,   N.     Wortham  ,   S.     Halford  ,   O.   
  Sieber  ,   N.     Mortensen  ,   A.     von Herbay  ,   T.     Gunther  ,   M.     Ilyas  , and   I.   
  Tomlinson  .   2005  .   CDC4 mutations occur in a subset of colorectal can-
cers but are not predicted to cause loss of function and are not associated 
with chromosomal instability.       Cancer Res.       65  :  11361    –    11366  .   
        36  .   Strohmaier  ,   H.  ,   C.H.     Spruck  ,   P.     Kaiser  ,   K.A.     Won  ,   O.     Sangfelt  , and   S.I.   
  Reed  .   2001  .   Human F-box protein hCdc4 targets cyclin E for proteoly-
sis and is mutated in a breast cancer cell line.       Nature    .   413  :  316    –    322  .   
        37  .   Mao  ,   J.H.  ,   J.     Perez-Losada  ,   D.     Wu  ,   R.     Delrosario  ,   R.     Tsunematsu  ,   K.I.   
  Nakayama  ,   K.     Brown  ,   S.     Bryson  , and   A.     Balmain  .   2004  .   Fbxw7/Cdc4 
is a p53-dependent, haploinsuffi   cient tumour suppressor gene.       Nature    . 
  432  :  775    –    779  .   
        38  .   Nowak  ,   D.  ,   M.     Mossner  ,   C.D.     Baldus  ,   O.     Hopfer  ,   E.     Thiel  , and   W.K.   
  Hofmann  .   2006  .   Mutation analysis of hCDC4 in AML cells identifi  es a 
new intronic polymorphism.       Int J Med Sci    .   3  :  148    –    151  .   
        39  .   Sharma  ,   V.M.  ,   J.A.     Calvo  ,   K.M.     Draheim  ,   L.A.     Cunningham  ,   N.   
  Hermance  ,  L.    Beverly  ,  V.    Krishnamoorthy  ,  M.    Bhasin  ,  A.J.    Capobianco  , 
and   M.A.     Kelliher  .   2006  .   Notch1 contributes to mouse T-cell leuke-
mia by directly inducing the expression of c-myc.       Mol. Cell. Biol.       26  : 
8022    –    8031  .   
        40  .   Minella  ,   A.C.  ,   M.     Welcker  , and   B.E.     Clurman  .   2005  .   Ras activity reg-
ulates cyclin E degradation by the Fbw7 pathway.       Proc. Natl. Acad. Sci. 
USA    .   102  :  9649    –    9654  .   
        41  .   Germano  ,   G.  ,   L.     del Giudice  ,   L.     Lo Nigro  ,   K.     Polato  ,   E.     Giarin  ,   M.   
  Paganin  , and   G.     Basso  .   2005  .   Comparative sequence analysis of incom-
plete DJH and TCR gene rearrangements in children with relapses of 
T-ALL.       Leukemia    .   19  :  1687    –    1689  .   
        42  .   Ory  ,   D.S.  ,   B.A.     Neugeboren  , and   R.C.     Mulligan  .   1996  .   A stable 
human-derived packaging cell line for production of high titer retrovirus/
vesicular stomatitis virus G pseudotypes.       Proc. Natl. Acad. Sci. USA    .   93  : 
11400    –    11406  .                             